Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE G-CSF / PEG-G-CSF MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 EUROPE G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION
4.4 EUROPE G-CSF / PEG-G-CSF MARKET
4.5 STRATEGIES TO THE ENTER THE MARKET
4.5.1 JOINT VENTURE (PARTNERSHIPS):
4.5.2 ACQUISITION:
4.5.3 LINE EXPANSION VIA COLLABORATION:
4.5.4 PRODUCT APPROVAL:
4.5.5 PRODUCT LAUNCH:
4.5.6 GEOGRAPHIC EXPANSION:
4.5.7 COST LEADERSHIP:
4.5.8 PRODUCT DEVELOPMENT:
4.6 EUROPE G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS
4.6.1 PATENT ANALYSIS
4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS
4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.6.4 THERAPEUTIC ASSESSMENT
4.6.5 KEY PRICING STRATEGIES
4.6.6 KEY PATIENT ENROLLMENT STRATEGIES
4.6.7 CONCLUSION
4.7 PIPELINE ANALYSIS FOR EUROPE G-CSF / PEG-G-CSF MARKET
5 EPIDEMIOLOGY
6 EUROPE G-CSF / PEG-G-CSF MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES
7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS
7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA
7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM
7.2 RESTRAIN
7.2.1 STRINGENT GOVERNMENTAL REGULATIONS
7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY
7.3 OPPORTUNITIES
7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS
7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS
7.4 CHALLENGES
7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY
7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF
8 EUROPE G-CSF/ PEG-G-CSF MARKET, BY INDICATION
8.1 OVERVIEW
8.2 NEUTROPENIA
8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT)
8.2.2 SEVERE CHRONIC NEUTROPENIA
8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA
8.2.4 NEUTROPENIA IN HIV PATIENTS
8.2.5 CLOZAPINE INDUCED NEUTROPENIA
8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS
8.2.7 CONGENITAL NEUTROPENIA
8.3 ONCOLOGY
8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY
8.3.2 OTHERS
8.4 CHRONIC AND AUTO IMMUNE DISEASES
8.5 BLOOD DISORDERS
8.6 GROWTH HORMONE DEFICIENCY
8.7 OTHERS
9 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DOSAGE
9.1 OVERVIEW
9.2 MONO
9.3 COMBINATION
10 EUROPE G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 SUBCUTANEOUS
10.3 INTRAVENOUS
11 EUROPE G-CSF/ PEG-G-CSF MARKET, BY PACKAGING
11.1 OVERVIEW
11.2 PRE FILLED SYRINGES
11.3 SINGLE USE VIALS
12 EUROPE G-CSF/ PEG-G-CSF MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS AND CLINICS
12.3 RESEARCH & ACADEMIC INSTITUTES
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITALS PHARMACY
13.3 RETAIL PHARMACY
13.4 ONLINE PHARMACY
13.5 OTHERS
14 EUROPE G-CSF/PEG-G-CSF MARKET, BY REGION
14.1 EUROPE
14.1.1 RUSSIA
14.1.2 TURKEY
15 EUROPE G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 PFIZER INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 VIATRIS INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 AMGEN INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 STADA ARZENEIMITTEL AG
17.4.1 COMPANY SNAPSHOT
17.4.2 COMPANY SHARE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.7 ACCORD HEALTHCARE
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 AMNEAL PHARMACEUTICALS LLC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 APOTEX INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BIOCON
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BIO SIDUS
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 CADILA PHARMACEUTICALS
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENTS
17.13 COHERUS BIOSCIENCES
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 DR. REDDY’S LABORATORIES LTD
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 FRESENIUS KABI AG
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 GENNOVA BIOPHARMACEUTICALS LIMITED
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD.
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENTS
17.18 INTAS PHARMACEUTICALS LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 KASHIV BIOSCIENCES, LLC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 KYOWA KIRIN CO., LTD.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 LUPIN
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENT
17.22 MUNDIPHARMA INTERNATIONAL.
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 NAPP PHARMACEUTICALS LIMITED
17.23.1 COMPANY SNAPSHOT
17.23.2 PRODUCT PORTFOLIO
17.23.3 RECENT DEVELOPMENT
17.24 RELIANCE LIFE SCIENCES
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 SANDOZ INTERNATIONAL GMBH
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENTS
17.26 SPECTRUM PHARMACEUTICALS, INC.
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 USV PRIVATE LIMITED
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET:
TABLE 2 EUROPE G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)
TABLE 7 EUROPE CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION)
TABLE 12 EUROPE MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 21 EUROPE HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 26 EUROPE HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION)
TABLE 31 EUROPE G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
TABLE 32 EUROPE G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 33 EUROPE NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 34 EUROPE ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 35 EUROPE G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)
TABLE 36 EUROPE G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)
TABLE 37 EUROPE G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)
TABLE 38 EUROPE G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)
TABLE 39 EUROPE G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)
TABLE 40 RUSSIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 41 RUSSIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 42 RUSSIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 43 RUSSIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)
TABLE 44 RUSSIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 45 RUSSIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)
TABLE 46 RUSSIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 47 RUSSIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)
TABLE 48 RUSSIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 49 RUSSIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)
TABLE 50 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 51 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 52 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 53 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 54 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 55 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 56 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 57 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 58 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 59 RUSSIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)
TABLE 60 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 61 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 62 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 63 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 64 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 65 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 66 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 67 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 68 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 69 TURKEY G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 70 TURKEY NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 71 TURKEY ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)
TABLE 72 TURKEY G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)
TABLE 73 TURKEY MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 74 TURKEY G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)
TABLE 75 TURKEY SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 76 TURKEY INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 77 TURKEY G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)
TABLE 78 TURKEY PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 79 TURKEY SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 80 TURKEY G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)
TABLE 81 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 82 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 83 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 84 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 85 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 86 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 87 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 88 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 89 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 90 TURKEY G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)
TABLE 91 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 92 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 93 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 94 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 95 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 96 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
TABLE 97 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)
TABLE 98 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)
TABLE 99 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)
List of Figure
FIGURE 1 EUROPE G-CSF / PEG-G-CSF MARKET: SEGMENTATION
FIGURE 2 EUROPE G-CSF / PEG-G-CSF MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE G-CSF / PEG-G-CSF MARKET: DROC ANALYSIS
FIGURE 4 EUROPE G-CSF / PEG-G-CSF MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE G-CSF / PEG-G-CSF MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE G-CSF / PEG-G-CSF MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE G-CSF / PEG-G-CSF MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE G-CSF / PEG-G-CSF MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE G-CSF / PEG-G-CSF MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE G-CSF / PEG-G-CSF MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN CANCER PROPHYLAXIS IN DEVELOPED COUNTRIES AND INITIATIVES TAKEN BY GOVERNMENTS ARE TO DRIVE THE EUROPE G-CSF / PEG-G-CSF MARKET FROM 2023 TO 2030
FIGURE 12 NEUTROPENIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE G-CSF / PEG-G-CSF MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE G-CSF / PEG-G-CSF MARKET
FIGURE 14 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2022
FIGURE 15 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2021-2030 (USD MILLION)
FIGURE 16 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, CAGR (2022-2029)
FIGURE 17 EUROPE G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, LIFELINE CURVE
FIGURE 18 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2022
FIGURE 19 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2021-2030 (USD MILLION)
FIGURE 20 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, CAGR (2023-2030)
FIGURE 21 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, LIFELINE CURVE
FIGURE 22 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 23 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
FIGURE 24 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 25 EUROPE G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2022
FIGURE 27 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2021-2030 (USD MILLION)
FIGURE 28 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, CAGR (2023-2030)
FIGURE 29 EUROPE G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, LIFELINE CURVE
FIGURE 30 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, 2022
FIGURE 31 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, 2021-2030 (USD MILLION)
FIGURE 32 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, CAGR (2023-2030)
FIGURE 33 EUROPE G-CSF/ PEG-G-CSF MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 35 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
FIGURE 36 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 37 EUROPE G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022)
FIGURE 39 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022)
FIGURE 40 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 EUROPE G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030)
FIGURE 43 EUROPE G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%)
